FORGED IN INDUSTRY.
BUILT FOR EMERGING BIOPHARMA.
The work between strategy and results is where we live.
A boutique partner for VC and PE-backed biopharma and medtech. Launch, market access, commercial transformation. Senior practitioners in the room with you, hands on the work from first call to last decision.
WHERE WE SHOW UP
Every engagement starts with a situation
We meet you where the pressure is.
Indication expansion
The evidence exists. The commercial architecture is conflicted.
Pre-launch readiness
The infrastructure gap reveals itself at the worst possible time.
PRE-MARKET
Scaling
What got you to launch won't get you through growth.
Commercial launch
The plan is ready. The infrastructure to execute it isn't.
LAUNCH & GROWTH
Performance plateau
Growth has stalled. That's a symptom, not the problem.
Commercial transformation
Built for a market that was just getting started.
PERFORMANCE & CHANGE
Coverage loss / crisis
Coverage disappears. Everything downstream stops with it.
Competitive entry
Defense without a plan is just a slower loss.
THREAT & NEW ENTRY
WHAT WE DO
Commercial capabilities built to remove obstacles.
We work between your team and the ecosystem around it: connecting evidence to access, access to execution.
MARKET ACCESS
Without access, nothing else reaches the patient.
We close the gap between what the FDA approved and what the payer will cover.
​
-
Prior auth pull-through strategy
-
Step therapy navigation and prescriber support
-
SP network optimization
-
PSP utilization at point of prescribing
-
Formulary tier positioning and contracting
COMMERCIAL OPERATIONS
The infrastructure that turns strategy into revenue.
Stood up at the speed your stage demands. Built to perform under the pressure that follows.
​
-
Field force deployment and redesign
-
Field force effectiveness (FFE)
-
CSO strategy, design, and optimization
-
Turning performance data into revenue decisions
-
Converting formulary wins into scripts
CLINICAL TO COMMERCIAL
Clinical strategy is commercial strategy.
Built for the market you're entering, not the one that looked good in the forecast.
​
-
Indication-specific value proposition and payer narrative
-
Evidence gap analysis for the new population
-
Label expansion and prescriber education strategy
-
Payer sequencing for new indication launch
-
Lifecycle positioning
HOW WE WORK
Senior people. On the work. From day one.
No lengthy onboarding. No methodology decks. Just experienced people getting oriented fast and focusing on what matters.
WE WORK ALONGSIDE YOU
We work as part of your team.
Same accountability, same standard, same skin in the game. The tools and partners already in the room stay in the room.
WE START BY LISTENING
We start with your situation.
The diagnosis comes before the prescription, every time.
WE MOVE AT YOUR SPEED
We move at the speed your stage demands.
Oriented in days. Decisive with incomplete information. The momentum carries.
WE STAY UNTIL IT WORKS
We stay through the inflection points.
Until the work holds without us in the room.
THIS IS HOW WE THINK
We have opinions. Here's one.
Perspectives from practitioners who have been inside the challenges, not observing from the outside.
HEOR & Market Access
The problem isn't a lack of evidence ... it's a lack of direction on where effort should be targeted.
Break the Silos: How Early Integration of HEOR and Market Access Drives Commercial Success
Most biopharma companies engage HEOR and Market Access too late, then scramble after Phase 3 with evidence that doesn't resonate with payers.
This paper makes the case for designing evidence backward from payer needs, starting years before launch.
